Compare Lululemon Athletica Inc (LULU) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs Zoetis Inc — how do they compare? Lululemon Athletica Inc trades at $113.65 (market cap $13.24B), while Zoetis Inc trades at $74.04 (market cap $31.59B). The key difference: Zoetis Inc is far larger — about 2.4× Lululemon Athletica Inc's market cap, and Zoetis Inc pays a 2.81% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| LULU | ZTS | |
|---|---|---|
Market Cap | $13.24B | $31.59B |
Sector | Consumer Cyclical | Health |
52-Week High | $224.03 | $156.76 |
52-Week Low | $105.43 | $71.91 |
Enterprise Value | $13.87B | $38.89B |
Dividend Yield | — | 2.81% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon trades at $116.63, up 0.26% today, amid bearish technical signals but strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.69 exceeding the $1.67 estimate. Revenue grew to $10.59B in 2025, with a net income margin of 17.13%. Recent news includes a $30M investment in nylon recycling startup Syntetica and resolution of a proxy battle with founder Chip Wilson, boosting shareholder confidence.
The outlook is mixed: valuation metrics like a P/E of 9.45 and EV/EBITDA of 5.41 suggest potential upside to the $129.29 consensus target, but technical bearishness and competitive pressures pose risks. Investors may find value in robust profitability and strategic initiatives, though macroeconomic headwinds and brand controversies require monitoring.
Zoetis (ZTS) trades at $75.33, down 1.61% amid mixed technical signals and ongoing securities litigation. The stock shows strong fundamentals with a 28.03% net margin and 67.75% ROE, supported by consistent revenue growth from $8.1B in 2022 to $9.47B in 2025. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026, with Q2 results pending. Analyst consensus remains positive with a $101.43 price target, though technical indicators show neutral momentum near key support at $75.
The outlook for ZTS is cautiously optimistic given robust profitability and analyst support, but significant legal overhangs and recent earnings volatility present near-term risks. Long-term growth in animal health markets offers upside, yet investors should monitor litigation developments and Q2 earnings for directional cues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
